Home
Contact Us
About Us
Advertise
Biotech
Finance
Tech News
Disclaimer
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
BioPharmaJournal
Home
Contact Us
About Us
Advertise
Biotech
Capricor Therapeutics (CAPR) Soars on Promising FDA Discussions: Is This a…
EMCORE (EMKR): A Takeover Target? Mobix Labs’ Bold Bid Shakes Things…
Telesis Bio Partnership with Beckman Coulter: A Potential Game-Changer for Synthetic…
Adaptive Biotechnologies Secures Key Regulatory Approval in Europe, Boosting ClonoSEQ
Seelos Therapeutics, Inc. (SEEL): A Strategic Move with SLS-002 in the…
Finance
Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance
Portage Biotech Inc. (NASDAQ: PRTG): A Closer Look at a Tumultuous…
Avalon GloboCare (ALBT) surges post Launch of Innovative Male Incontinence Device
Reason why Inspirato Incorporated (ISPO) has high trading volume today
Clearmind Medicine Inc (CMND) briefly surges and here’s why
Tech News
Aehr Test Systems (NASDAQ: AEHR) Receives an Order of $10.8 Million…
Tauriga Sciences Inc (OTCMKTS:TAUG) Could React on New Aegea Rapid Test…
Micro and Macro Tailwinds Converge for KULR
ISWH and the Rebirth of the Crypto Cycle
Disclaimer
Home
Tags
CRIS Stock
Tag: CRIS Stock
Curis, Inc. (NASDAQ: CRIS) Will Present Data on Its TakeAim Leukaemia...
Gavins Felicity
-
June 14, 2022
0
Curis, Inc. (NASDAQ: CRIS) Recently Announced Its Partners’ Publication on Emarvusatib
Kate Hudson
-
March 15, 2022
0
Curis Inc. (NASDAQ: CRIS) Reports Positive Dose Escalation And Expansion Results...
Kate Hudson
-
January 21, 2022
0
Curis Inc. (NASDAQ: CRIS) Expands Executive Leadership With Addition Of Three...
Gavins Felicity
-
January 13, 2022
0
Curis Inc. (NASDAQ: CRIS) Doses First Subject in The Combination Therapy...
Kate Hudson
-
November 19, 2021
0
Recent Post
Capricor Therapeutics (CAPR) Soars on Promising FDA Discussions: Is This a...
Gavins Felicity
-
October 1, 2024
0
Capricor Therapeutics (CAPR) saw its stock price skyrocket by over 50% after announcing its plans to file a Biologics License Application (BLA)...
EMCORE (EMKR): A Takeover Target? Mobix Labs’ Bold Bid Shakes Things...
October 1, 2024
Telesis Bio Partnership with Beckman Coulter: A Potential Game-Changer for Synthetic...
September 26, 2024
Adaptive Biotechnologies Secures Key Regulatory Approval in Europe, Boosting ClonoSEQ
September 26, 2024
Seelos Therapeutics, Inc. (SEEL): A Strategic Move with SLS-002 in the...
September 24, 2024